Category ""
ADVERTISING
We are a multidisciplinary lab interested in the molecular mechanisms underlying tumor progression and immune evasion. Our work is inspired by clinical puzzles and we develop and employ a wide array of molecular biology, biochemistry, and in vivo approaches with the vision and mission of guiding rational combination therapies.
Master students and Post-docs: Contact Anna Obenauf with a letter of intent detailing why you want to join the lab. What are the molecular mechanisms behind cancer? How can we exploit the vulnerabilities of cancer cells to find opportunities for new therapies?
Here we investigated 19 skin tumor types by analyzing off-target reads from commonly available next-generation sequencing data for viral pathogens. We identified human papillomavirus 42 (HPV42) in...
After studying senescence in AML as part of his MD thesis, he joined the Obenauf Lab to discover new therapeutic vulnerabilities in osteosarcoma together with Andri.
How tumors become resistant to cancer therapies and how cancer cells evade the recognition and eradication by the immune system remain among the most enigmatic questions in cancer biology.
Anna Obenauf ist Gruppenleiterin des Obenauf Lab, das am Institut für Molekulare Pathologie (IMP) Krebsmetastasen und Therapieresistenz erforscht. Sie promovierte an der Medizinischen Universität Graz und war Post Doc am Memorial Sloan Kettering Cancer Center in den USA.
Directory of publications by the Obenauf research group at IMP: scientific papers listed by year, with title, authors, scientific journal and other information on the publications.
Our lab studies the molecular determinants of response and resistance to targeted and immunotherapies with the vision and mission to guide rational combination therapies to achieve durable responses in cancer patients.
Anna Obenauf, Senior Group Leader at the IMP, will head the research focused on understanding how the immune system interacts with early metastatic cancer cells, exploring why some evade immunity while others are eliminated.
Lukas Leiendecker, Pauline S Jung, Izabela Krecioch, Tobias Neumann, Alexander Schleiffer, Karl Mechtler, Thomas Wiesner, Anna C.Obenauf. LSD1 inhibition induces differentiation and cell death in Merkel cell carcinoma.